American Diabetes Association awards Aleksandar Kostic, PhD, of Joslin Diabetes Center, $1.625M for the development of a novel experimental system designed to improve our understanding about how bacteria in the gut (the gut “microbiome”) may contribute to the autoimmune attack that leads to type 1 diabetes.
Participants in Joslin's Why WAIT (Weight Achievement and Intensive Management) program lost substantial amounts of weight, and even those who maintained relatively little loss of weight after five years demonstrated reduced risks of cardiovascular disease.
People with any form of diabetes are at greater risk of developing cardiovascular conditions than people without the disease. Moreover, if they undergo an operation to open up a clogged artery by inserting a “stent” surgical tube, the artery is much more likely to clog up again. However, researchers at Joslin Diabetes Centers now have uncovered an explanation for why these procedures often fail, which may lead toward better alternatives.
Laurie J. Goodyear, PhD, at Joslin Diabetes Center will be part of the NIH's new MoTrPAC consortium and will help map molecular changes from physical activity.
Most people struggle with their weight and are less active than ever before. Taken together, this toxic lifestyle can lead to serious health problems. The truth is that 86 million American adults—more than one out of three—have prediabetes. What’s scarier is that nine out of 10 don’t know they have it.
Joslin Diabetes Center investigators are shedding light on how the success of such microbiome treatments may be affected by genetics of the individual or animal being treated.
Genes play a role in how people with type 2 diabetes at high risk of cardiovascular disease risk respond to intensive glycemic control as an intervention to prevent the disease.
There are no established drugs to improve angiogenesis in diabetes. However, researchers at Joslin Diabetes Center now have identified a gene called CITED2 in a molecular pathway that may offer targets for drugs that treat these conditions by strengthening angiogenesis.
Researchers at Joslin Diabetes Center now have demonstrated that umbilical cells from children of obese or overweight mothers show impaired expression of key genes regulating cell energy and metabolism, compared to similar cells from babies of non-obese mothers.
But some studies are showing that these reactive oxygen species (ROS) molecules sometimes can aid in maintaining health—findings now boosted by a surprising discovery from Joslin Diabetes Center researchers.
Jennifer K. Sun, M.D., MPH, Investigator in the Section on Vascular Biology at Joslin Diabetes Center, an Ophthalmologist in Beetham Eye Institute (BEI) at Joslin Diabetes Center and Associate Professor at Harvard Medical School, has been granted an RPB Physician-Scientist Award by Research to Prevent Blindness (RPB).
Most pregnant women with well-controlled diabetes give birth to healthy children. But their babies run much higher risks of birth defects than babies born to women without diabetes, because very early in embryonic development, the babies are exposed to higher levels of glucose in maternal blood.
Researchers at Joslin Diabetes Center have announced the results of a study that may change how nutrition therapy is delivered to overweight and obese patients with type 2 diabetes.
Joslin Diabetes Center, a research and clinical affiliate of Harvard Medical School, today announced a newly signed collaboration with Sanofi (EURONEXT: SAN and NYSE: SNY) which extends their ongoing collaboration in exploring novel targets for treatment of diabetes.
George L. King, M.D., Chief Scientific Officer at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, has been selected to receive the 2016 JDRF Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award.
– Gordon Weir, M.D., Diabetes Research and Wellness Foundation Chair, Co-Head of Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, has been selected as the recipient of the American Diabetes Association’s (ADA) 2016 Albert Renold Award.
In type 1 diabetes, the immune system attacks the body’s own insulin-producing cells. Scientists understand reasonably well how this autoimmune attack progresses, but they don’t understand what triggers the attack or how to stop it, says Stephan Kissler, Ph.D., Investigator in the Section on Immunobiology at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.
In obesity, the body’s immune system can treat tissues as if they are suffering from a low-grade chronic infection. This obesity-induced inflammation is an important contributor to insulin resistance, a condition that can progress into type 2 diabetes.
In a national clinical trial led by Joslin Diabetes Center’s Beetham Eye Institute, ultrawide field (UWF) scanning technology significantly improved the ability of experts at a remote central location to identify diabetic retinopathy in a patient, and to judge whether the eye disease warranted referring the patient to an ophthalmologist for further care.
Rohit N. Kulkarni, M.D., Ph.D., Senior Investigator in the Section on Islet Cell and Regenerative Biology at Joslin Diabetes Center, has been named Professor of Medicine by Harvard Medical School.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right